A Phase I/II Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma

Status
Active
Cancer Type
Multiple Myeloma
Trial Phase
Phase I
Phase II
Eligibility
18 and over, Male and Female
Study Type
Treatment
NCD ID
NCT01101594
Protocol IDs
IM-T-hLL1-DOX-01 (primary)
Study Sponsor
Immunomedics, Incorporated

Summary

This study is a Ph I trial to test the safety of the study drug, hLL1-DOX at different dose levels in patients with recurrent multiple myeloma. HLL1 is also known as milatuzumab and is attached to doxorubicin in this clinical trial.

Objectives

In this clinical research trial, hLL1-DOX will be administered on days 1, 4, 8 and 11. This treatment cycle will be repeated every 3 weeks as long as patients continue to tolerate it, for a maximum of 8 treatment cycles (approximately 6 months).

Treatment Sites in Georgia


Georgia Cancer Specialists - Hillandale
5700 Hillandale Drive
Building 200 Suite 250
Lithonia, GA 30058
www.gacancer.com

Study Coordinator:
Christopher Moore
(770) 496-9427

Doctors:

Simbo O. Aduloju MD